World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A new tuberculosis treatment regimen for drug-resistant tuberculosis, endorsed by WHO, that is efficacious, safe, and shorter than previous regimens could have a role in reducing tuberculosis deaths.51”
From Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Sustainable Development Goals: Law, Theory and Implementation
(2018) · Edward Elgar Publishing eBooks · doi:10.4337/9781786438768 · Cited by 1,925
The World Health Organization Global Action Plan for antimicrobial resistance
Mendelson, M., & Matsoso, M. P. (2015) · South African Medical Journal · doi:10.7196/samj.9644 · Cited by 1,155
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTreatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014) · European Respiratory Journal · doi:10.1183/09031936.00193413 · Cited by 586
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Research works printed but not linked: 1
- Dooley K , Rosenkranz S , Conradie F , et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Conference on Retroviruses and Opportunistic Infections (CROI). Washington, USA. March 4–7, 2019. Available from: https://www.croiconference.org/abstract/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial/
Cited by
Items 101–200 of 302
COVID-19, Law & Regulation: Rights, Freedoms, and Obligations in a Pandemic
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · doi:10.1093/oso/9780192896742.001.0001 · Cited by 14
Deciphering the mechanism of action of antitubercular compounds with metabolomics
Sakallioglu, I. T., Barletta, R. G., Dussault, P. H., & Powers, R. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.034 · Cited by 9
“Pretomanid has been extensively studied as a candidate for the treatment of both drug-susceptible and drug-resistant TB [87,88].”
BackgroundSheng, L., Li, X., Weng, F., Wu, S., Chen, Y., & Lou, L. (2022) · Journal of Tropical Medicine · doi:10.1155/2022/5071816 · Cited by 7
“Quality evaluation was achieved using the Cochrane’s Risk of Bias Tool [36] according to the following aspects: [1] random sequence generation, [2] allocation concealment, [3] blinding of participants and personnel, [4] blinding of outcome assessors, [5] incomplete outcome data, [6] selective outcome reporting, and [7…”
BackgroundMethodRoss, J. E., Perumal, R., Wolf, A., Zulu, M., Guzman, K. J., Seepamore, B., Reis, K., Nyilana, H., Hlathi, S., Narasimmulu, R., et al. (2023) · Trials · doi:10.1186/s13063-023-07520-9 · Cited by 7
“Until recently, treating MDR-TB has required complex regimens with long duration and severe adverse events [3].”
BackgroundAlam, S. M., Nigar, N., Rasheed, M. W., & Amin, L. (2024) · Frontiers in Physics · doi:10.3389/fphy.2024.1383216 · Cited by 7
Deun, A. V., Bola, V., Lebeke, R., Kaswa, M. K., Hossain, M. A., Gumusboga, M., Torrea, G., de Jong, B. C., Rigouts, L., & Decroo, T. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac037 · Cited by 7
Prevalence of pulmonary tuberculosis in Al-Najaf governorate, Iraq
Al-Hadraawy, S. K., ALhadrawi, K. K., Aljanaby, I. A. J., Aljanaby, A. A. J., & Zabibah, R. S. (2022) · F1000Research · doi:10.12688/f1000research.121881.1 · Cited by 7
“In 2020, milestone of about more than 30% reduction in the absolute number of PTB deaths between 2015 and 2020.(9) Al-Najaf Governorate is one of the most important holy cities in Iraq, about 180 kilometers south of Baghdad capital of Iraq and its estimated population about 1,500,000 people and it is crowded Governora…”
BackgroundLai, C.-C., Lu, C.-T., Kao, K., Lu, M., Ko, W., & Hsueh, P. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.03.002 · Cited by 7
Abdelaal, H. F. M., Berube, B. J., Podell, B. K., Harband, M. H., Gary, H. E., Perez-Jaimes, M., Ackart, D. F., Reese, V. A., Larsen, S. E., Pecor, T., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00066-z · Cited by 7
Fakih, T. M., Suarantika, F., Hidayat, A. F., Ramadhan, D. S. F., & Muchtaridi, M. (2025) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2025.2531748 · Cited by 7
“The World Health Organization (WHO) estimates that about 10 million people worldwide develop TB every year, with approximately 1.5 million deaths annually, making it one of the top infectious disease killers [1,2].”
InfluentialSmith, N., Quan, D. H., Nagalingam, G., Triccas, J. A., Rendina, L. M., & Rutledge, P. J. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00150k · Cited by 6
Gomare, M., Bhide, S., Deshmukh, R. D., Kaipilyawar, S. B., Puri, V., Moonan, P. K., Khetade, D. K., Nyendak, M. R., Yeldandi, V. V., Smith, J. P., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7212a2 · Cited by 6
“php?lid=3538 complexity of treating DRTB compared with that of treating drug-susceptible TB, including longer treatment durations, need for second-line drug regimens, more frequent drug-related adverse events, a higher prevalence of treatment relapse, and higher mortality (3).”
BackgroundSheereen, S., Manva, M. Z., Sheereen, S., & Patil, N. N. (2024) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_224_23 · Cited by 6
Ma, X., Zhang, R., Cai, X., Lang, Y., Wang, H., & Li, J. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s468543 · Cited by 6
Alhawarri, M. B., Al-Thiabat, M. G., Dubey, A., Tufail, A., Banisalman, K., Jabal, G. A. A., Alkasasbeh, E., Al-Trad, E., & Alrimawi, B. H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313094 · Cited by 7
“According to the World Health Organization, breast cancer is responsible for one in every eight cancer diagnoses, with an estimated 2.3 million new cases in 2020, highlighting its wide-spread impact and the ongoing need for effective treatments [2,3].”
InfluentialYadav, S. (2022) · Cureus · doi:10.7759/cureus.32963 · Cited by 6
“It was upgraded to WHO group B anti-TB drugs in 2018 [5].”
MethodAguilar‐Jiménez, J. R., Pelissari, D. M., & Díaz-Quijano, F. A. (2023) · Tropical Medicine & International Health · doi:10.1111/tmi.13945 · Cited by 6
“Drug resistance is one of the main issues in eradicating tuberculosis (TB) as a public health problem [1, 2].”
BackgroundAbbasian, S., Heidari, H., Tadi, D. A., Kardan-Yamchi, J., Taji, A., Darbandi, A., Asadollahi, P., Maleki, A., & Kazemian, H. (2024) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2024.100430 · Cited by 6
“Any drug resistance is defined as resistance to any drug regardless of mono-resistance or MDR [9,10].”
BackgroundInfluentialWhole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia
Diriba, G., Mollalign, H., Meaza, A., Getu, M., Zerihun, B., Alemu, A., Dagne, B., Abebaw, Y., Weldemariam, A. G., Bashea, C., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01271-1 · Cited by 5
Plasma lipidomic analysis reveals distinct lipid alterations in patients with pulmonary tuberculosis
Zhang, C., Cai, M., Cai, H., & Chen, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02835-6 · Cited by 5
“As a persistent global public health challenge, tuberculosis, particularly drug-resistant PTB, remains a significant burden, with stagnating declines in incidence and increasing mortality rates [3–6].”
Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis
Sikandar, M., & Xing, L. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107861 · Cited by 7
Zhou, X., Fang, G.-Y., Xie, Y., Wei, A., & Huang, F. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.871321 · Cited by 5
“Considering the utility of isoniazid preventive therapy (IPT) in reducing tuberculosis infection in pregnant women and fetuses after pregnancy, the WHO strongly recommends IPT treatment for latent tuberculosis infection in patients infected with HIV (including pregnant women) (7).”
BackgroundRetractedTreatment Outcome of MDR/RR TB in a Resource-Constrained Setup: A Four-Year Retrospective Analysis
Omer, A. A., Meshesha, M. D., Ajema, A. T., & Yoo, S. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s377238 · Cited by 5
“Globally, due to the increasing trend of cases both estimated and reported, it is a primary focus area; multiple efforts are being introduced to strengthen its early detection and treatment with its favorable outcomes.(2,3) Estimating the MDR TB disease burden depends on the extent of bacteriological confirmation of T…”
BackgroundNew Anti-tuberculous Drugs: Bedaquiline, Delamanid, and Pretomanid
Fong, I. W. (2023) · Emerging infectious diseases of the 21st century · doi:10.1007/978-3-031-26078-0_9 · Cited by 5
Xuan, X., Li, Y., Cao, G., Zhang, R., Hu, J. H., Jin, H., & Dong, H. (2023) · Vascular Medicine · doi:10.1177/1358863x231198055 · Cited by 5
“36 Future studies should consider the impact of long-term FQ exposure on aortic disorders.”
BackgroundOtto-Knapp, R., Bauer, T. T., Brinkmann, F., Feiterna‐Sperling, C., Friesen, I., Geerdes-Fenge, H. F., Hartmann, P., Häcker, B., Hauer, B., Haas, W., et al. (2023) · Pneumologie · doi:10.1055/a-2182-1609 · Cited by 5
Clofazimine inhibits innate immunity against Mycobacterium tuberculosis by NF-κB
Li, X., Luo, X., Wang, B., Fu, L., Chen, X., & Lu, Y. (2024) · mSphere · doi:10.1128/msphere.00254-24 · Cited by 6
“Current TB treatment regimen requires multiple drug combinations and can last up to 6 months for drug-sensitive TB, 18–20 months for MDR/XDR-TB, and possibly longer if new drug resistance is identified (29–34).”
BackgroundEarly bactericidal activity of sitafloxacin against pulmonary tuberculosis
Nie, L., Tong, J., Wu, G., Du, J., Shang, Y., Wang, Y., Wu, Z., Xu, Y., Ren, Y., Rao, Y., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01645-24 · Cited by 5
Shi, J., Zheng, D., Su, R., Ma, X.-G., Zhu, Y., Wang, S., Chang, W., & Sun, D. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10730-y · Cited by 5
“Because oftheir potent antibacterial activity [20], imipenem and meropenem have been classified by the WHO as group C anti-TB drugs forthe treatment of patients with MDR-TBor rifampicin-resistant TB [21–23].”
Nasasira, M., Kalyango, J. N., Mupere, E., & Baluku, J. B. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s381800 · Cited by 5
“Clinical Characteristics About half (52.5%, n=219) of the participants were HIV positive, 46% (n=192) were newly diagnosed DR-TB and 78.9% (n=329) had RR-TB.”
BackgroundMethodInfluentialYıldırım, K., Karaçolak, A. İ., Kutlu, E., Emen, F. M., Ali, M. A., Şimşek, E., Çoban, A. Y., Ataş, C., & Yeşilkaynak, T. (2025) · Journal of Sulfur Chemistry · doi:10.1080/17415993.2025.2555480 · Cited by 4
“As stated in the WHO reports, for many drugs used for treatment, resistance to treatment develops over time and therefore the effectiveness of drugs decreases [9].”
Otto-Knapp, R., Bauer, T. T., Brinkmann, F., Feiterna‐Sperling, C., Friesen, I., Geerdes-Fenge, H. F., Hartmann, P., Häcker, B., Heyckendorf, J., Kuhns, M., et al. (2024) · Respiration · doi:10.1159/000539410 · Cited by 4
“…patients with MDR-TB can be offered treat-ment for 9 – 12 months with the oral, non-modi fi able drug combination of bedaquiline, levo fl oxacin or moxi-fl oxacin, protionamide (can be replaced by linezolid 600 mg/d), ethambutol, pyrazinamide, high-dose isoniazid and clofazimine [4, 17] (Box 2).”
Lalashowi, J., Mvungi, H., Mwaisango, Z., Pamba, D. I., Mohamed, A., Gitige, C. G., Shayo, P. J., Lekule, I. A., Kigumi, H. O., Kisonga, R. M., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088556 · Cited by 6
“The findings from this study are set to inform the National Tuberculosis and Leprosy Programme on different factors that have been found to influence acceptability, adherence and satisfaction of the modified shorter MDR regimen to improve MDR services in the country.”
Fang, Q. Z., Li, X., Lu, Y., Gao, J., Wu, Y., Chen, Y., & Che, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1641385 · Cited by 6
Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?
Kamada, K., & Mitarai, S. (2021) · Antibiotics · doi:10.3390/antibiotics11010019 · Cited by 4
“In addition, the 2020 revision of the guidelines recommend switching from injections to BDQ in short-term regimens [11].”
BackgroundRandomized control study of the use of faropenem for treating patients with pulmonary tuberculosis
Shangguan, Y., Guo, W., Feng, X., Shi, Y., Li, X., Pan, Z., Hu, M., Shi, J., Ding, C., Xia, J., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.388 · Cited by 5
“Carbapenems have demonstrated potent anti-TB activity [9–11] and excellent tolerability in Multidrug-resistant Tuberculosis/Extensively Drug-resistant Tuberculosis treatment and are listed by the World Health Organization (WHO) as group C anti-TB agents [12 , 13] .”
Prediction Analysis of Mycobacterium Tuberculosis by using Deep Learning Model
Khanna, D., Garg, N., & Sharma, P. (2023) · International Conference on Research Methodologies in Knowledge Management, Artificial Intelligence and Telecommunication Engineering (RMKMATE) · doi:10.1109/rmkmate59243.2023.10369599 · Cited by 5
“The threat of drug-resistant mutations [5], [6] increases due to chemotherapy process which consumes 9 to 12 months, or more months to complete [7].”
BackgroundNofal, I. M. M., AbdelHalim, H. A., Maraghy, A. A. E., Awad, A. M., & Farrag, M. A. (2024) · Egyptian Journal of Bronchology · doi:10.1186/s43168-024-00348-0 · Cited by 4
Characterization of Clofazimine as a Potential Substrate of Drug Transporter
Jony, M. R., Cho, Y., Long, N. P., Shin, H. J., & Shin, J. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02158-21 · Cited by 4
“World Health Organization (WHO) MDR-TB treatment guidelines (14, 15).”
BackgroundDeepa, N., Prabakeran, S., & Devi., T. (2022) · International Conference on Advancements in Smart, Secure and Intelligent Computing (ASSIC) · doi:10.1109/assic55218.2022.10088322 · Cited by 4
“(v) Insurance providers for patients, hospitals, and their instruments have insurance coverage details, claim history, and profitability portfolio of various services provided by them [8-11].”
BackgroundIruedo, J., & Pather, M. K. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20146423 · Cited by 6
“Other medications, such as linezolid and fluoroquinolones may also cause QT-interval prolongation [44,45].”
BackgroundSynthesis of Levoglucosenone‐derived Thiosemicarbazones as Promising Antituberculosis Agents
Tsai, Y.-H., Aira, N., Ensinck, D., Banchio, C., Gramajo, H. C., Suárez, A. G., Spanevello, R. A., & Sarotti, A. M. (2023) · ChemistrySelect · doi:10.1002/slct.202303776 · Cited by 4
The evolution of the European Respiratory Journal : weathering the publishing pandemic
Kolb, M. R. J., Chalmers, J. D., & Humbert, M. J. C. (2021) · European Respiratory Journal · doi:10.1183/13993003.00084-2021 · Cited by 4
Han, Y.-R., Wang, T.-H., Gong, W.-P., Liang, J.-Q., & An, H.-R. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s351317 · Cited by 4
“Drug-resistant TB has a complex treatment regimen, long course of treatment, and poor efficacy, which makes global TB control an enormous challenge.(2) Studies have shown that the level of CD4 in peripheral blood of patients with multiple drug-resistant tuberculosis (MDR-TB) and its production of γ-IFN are significant…”
BackgroundBhattarai, S., Tiwari, V. S., Tam, B., Rozen, A., Soffer, A., Durbah, S., Eisdorfer, S. A., Giannoulis, A., Goldfarb, D., & Akabayov, B. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae027 · Cited by 3
Sudhakar, P., Acharya, K., & Kini, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1626909 · Cited by 3
Wang, T., Zhou, C., Shang, L., & Zhou, X. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08568-3 · Cited by 3
“Patients generally choose to stop medication after the symptoms have improved slightly, thus resulting in drug resistance and further aggra-vating the difficulty of treatment [55].”
BackgroundManagement of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq
Tesfahun, H. M., Al-Salihi, L., Al-Ani, N. A., Mankhi, A. A., Mohammed, A., Lim, C. A. E., Al-Hilfi, R. A., Jouego, C. G., Decroo, T., Moussally, K., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296952 · Cited by 3
A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management
Alfaqeeh, M., Santoso, P., Alffenaar, J. C., & Pradipta, I. S. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s517965 · Cited by 5
“63 Diagnostic delays in the timely and accurate identification of DR-TB pose a significant challenge, delaying treatment initiation and increasing transmission risks.”
Simorangkir, L., Sinaga, S. P., Ginting, F. S. H. B., & Rupang, E. R. (2022) · Elisabeth Health Jurnal · doi:10.52317/ehj.v7i1.409 · Cited by 3
“…dan digunakan terutama ketika bakteri TB resisten adalah keadaan kuman Mycobacterium tuberculosis sudah tidak dapat ditangani dengan beberapa obat lini pertama setidaknya isoniazid dan rifampisin obat tersebut adalah jenis obat anti tuberkulosis (Muhammad & Fadli, 2019;Maksum, et al., 2018).”
BackgroundMeta-Analysis Study: Environmental Risk Factors of Tuberculosis (TB)
Jannah, R. Z., Azizah, R., Jalaludin, J. B., Sulistyorini, L., & Lestari, K. S. (2023) · JURNAL KESEHATAN LINGKUNGAN · doi:10.20473/jkl.v15i2.2023.84-91 · Cited by 3
Majumdar, T., Banik, A., Allada, V., & Das, B. (2023) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2023.100399 · Cited by 4
Santos, A. P., Benace, C. J., Leung, J., Kritski, A. L., & Mello, F. C. D. Q. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09993-8 · Cited by 3
“From observational studies to randomized clinical trials, all of them contributed to the current WHO recommendations [7–10].”
BackgroundAnti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers
Mitton‐Fry, M. J., Cummings, J. E., Lu, Y., Armenia, J. F., Byl, J. A. W., Oviatt, A. A., Bauman, A., Robertson, G. T., Osheroff, N., & Slayden, R. A. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00743 · Cited by 3
Chen, Z., Wang, Q. J., Ma, Q., Chen, J., Kong, X., Zeng, Y., Liu, L., Lu, S., & Wang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-86951-7 · Cited by 3
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0004 · Cited by 3
SINGAGARI, S., & Sundararajan, R. (2022) · Journal of Research in Pharmacy · doi:10.29228/jrp.160 · Cited by 3
“To address this serious health issue, continuous efforts must be devoted to identifying and developing novel drug molecules as potent antibacterial agents [3-4].”
BackgroundFeschenko, Y. I., Lytvynenko, N. А., Гранкіна, Н. В., Pogrebna, M., Senko, Y. О., & Protsyk, L. M. (2022) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2022-30-2-5-11 · Cited by 3
Belay, G., Getachew, H., Birku, T., Tadese, A., Gashaw, Y., Getie, M., Molla, T., Tarekegn, M., Mekonnen, D. S., & Abate, A. (2025) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2025.100528 · Cited by 2
“[69] and 3.4 % of new TB cases globally [70].”
InfluentialValidated HPLC Method for the Pharmacokinetic Study of Linezolid in Rats
Liu, J., Pang, Y., Wang, P., Li, W., & Dong, J. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70107 · Cited by 2
Viljoen, L., Draper, H. R., Castillo-Carandang, N. T., Suryavanshi, N., Marthinus, A., Cheong, A. M. A., Ocampo, J. D. D., Dhumal, G., Bagchi, S., Wademan, D. T., et al. (2025) · IJTLD OPEN · doi:10.5588/ijtldopen.25.0309 · Cited by 3
Unmasking rifampicin mono-resistance in tuberculosis patients in Cross River State, Nigeria
Ochang, E. A., Udoh, U. A., Otu, A. A., Ewa, A., Ibe, C., & Moore, D. (2025) · Discover Public Health · doi:10.1186/s12982-025-00926-7 · Cited by 2
Allel, K., Palmer, T., Jaoude, G. J. A., Korotych, O., Yedilbayev, A., Vilc, V., Corloteanu, A., Macari, M., Evghenia, C., Laticevschi, D., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018099 · Cited by 2
“Univariate sensitivity analyses for each country are graphically depicted in online supplemental figures 6 and 7.”
Bakht, M., Khoei, S. G., Aria, N., Rahimi, S., Sadeghi, H., Sabzi, S., & Babaei, A. (2025) · Sensors and Actuators Reports · doi:10.1016/j.snr.2025.100415 · Cited by 2
Liu, R., Xu, S., Liu, S., Xu, M., Li, J., Wang, A., Li, W., Zhan, L., Ruan, K., Fei, C., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01346-z · Cited by 3
“The World Health Organization (WHO) has identi fi ed multidrug-resistant (MDR) Klebsiella pneumoniae ( K. pneumoniae ), Escherichia coli ( E. coli ), and Salmonella as critical pathogens that urgently require new treatment strategies 3 .”
Profile of Children With Tuberculosis in a Pediatric Intensive Care Unit in Mumbai
Renji, S., Solomon, R., Wankhade, D., Udani, S. V., & Udani, V. P. (2021) · Indian Pediatrics · doi:10.1007/s13312-021-2394-0 · Cited by 2
“GeneXpert testing was positive in an additional 15 patients who were culture negative or culture positive but DST was not done, and showed rifampicin resistance in 6.”
BackgroundInfluentialLuo, P.-P., Li, W., Liu, F., Tian, Y.-H., Chen, L.-Y., & Liu, Y. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.39.2.6364 · Cited by 2
(2023) · doi:10.1002/prot.26504 · Cited by 2
“Enhanced by increasing drug resistance, tuberculosis poses an outstanding public health threat.(2) Therefore, the development of novel antimycobacterial agents is urgently needed.”
BackgroundYatskevich, N., Gurevich, G. L., Skryagina, E. M., & Gurbanova, E. (2023) · Tuberculosis and lung diseases · doi:10.58838/2075-1230-2023-101-6-34-41 · Cited by 2
Zhou, Q., Pu, N., Xu, G., Liu, H., Jia, X., Wang, X., & Xu, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315512 · Cited by 2
“FQs are frequently used to treat MDR-TB patients as an important component of the WHO-recommended short-course treatment regimen for TB [50, 51].”
Chorna, Y., Lukash, I.-G., Kalancha, Y., Tonkonoh, L., Abdullaeva, M., Adenov, M., Chuprynska, M., Hasanova, S., Ibragimova, O., Jazybekova, P., et al. (2025) · BMC Global and Public Health · doi:10.1186/s44263-025-00136-y · Cited by 5
Bereda, G. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70317 · Cited by 2
“The determinants linked to MDR-TB include age, sex, educational level, behavioral (addiction, smoking, and alcoholism), clinical (HIV), prior treatment history, type of resistance, accessibility to health services, reduction in social protection policies, and social contexts of poverty [6].”
Shang, L., Li, G., Lin, Q., Ou, M., Liang, J. B., Xiao, G., Wang, Z., Cui, S., Zhang, T., Liu, L., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.103 · Cited by 2
Makarova, M. V., Mikhailova, Y. D., Khachaturiants, E., & Litvinov, V. I. (2022) · Tuberkulez i socialʹno značimye zabolevaniâ · doi:10.54921/2413-0346-2022-10-4-47-94 · Cited by 6
Önür, S. T., Ortaköylü, M. G., İliaz, S., & Alkan, F. (2021) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2021.7596 · Cited by 2
“Moreover, low body mass index, smoking history, and poorly controlled diabetes increase TB susceptibility in elderly (14-17).”
Australian recommendations for the management of drug-resistant tuberculosis, 2023
Stapledon, R., & Donnan, E. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.48 · Cited by 1
Disseminated TB With IRIS Presenting as a Pancreatic Mass in Newly Diagnosed HIV: A Case Report
Akbar, S. N., & Mariuz, P. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae746 · Cited by 1
“…lung nodules, and bilateral pleural effusions, yet with improvement in the size of the pancreatic mass and lymphadenopathy in the setting of negative respiratory, gastric, and ascitic microbiologic results for TB, argue against treatment failure and development of multidrug resistance [11, 19].”
Serum zinc level and its association with pulmonary tuberculosis
Kianifar, F., Dastjerdi, A. R. V., Maram, M. M., Bagtash, K., Zamanian, M. Y., Eslami, M., Fardyar, R., & Farazi, A. (2024) · Immunopathologia Persa · doi:10.34172/ipp.2025.40537 · Cited by 1
Yang, S., Feng, Y., Yang, K., Pu, J., & Wang, P. (2025) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_33_25 · Cited by 1
Soedarsono, S., Permatasari, A., Agustiyanto, C., & Rampengan, V. R. C. (2025) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2025.08.001 · Cited by 1
Abegaz, E. A., Mesfin, M. A., & Bazie, G. W. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11816-3 · Cited by 1
“Tuberculosis (TB) strains that develop resistance to anti-TB drugs are significantly more difficult to treat than drug-susceptible strains and pose a substantial challenge to patients, healthcare workers, and health systems [1, 2].”
Khedr, M. H., Abdelaziz, A. E. M., Albadwi, F., Youssef, F. S., Abdelmaksoud, E. M., Mekky, A. E., Saied, E., El‐Tabakh, M. A. M., Abdelmouty, E. S., Eldiasty, J. G., et al. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100646 · Cited by 2
“Of particular concern are the ESKAPE pathogens ( Enterococcus, Staphylococcus, Klebsiella, Acinetobacter, Pseudomonas, Enterobacter, and Escherichia coli ), which are responsible for a large proportion of hospital-and community-acquired infections and display high levels of resistance [3].”
Gupta, A., Pais, C. C., & Babu, S. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1361 · Cited by 1
Oelofse, S., Esmail, A., Perumal, T., Swanepoel, J., Meier, S., Mbuthini, L., Jaumdally, S. Z., Scott, A. J., Kühn, L., Pooran, A., et al. (2026) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00489-9 · Cited by 1
Expanding treatment options for syphilis during pregnancy: a review of alternatives to penicillin
Townsend, C. L., Mofenson, L., Gottlieb, S., Peters, R. P. H., Mitjà, J., Pérez‐Mañá, C., Abrams, E. J., Delany‐Moretlwe, S., Lockman, S., Waitt, C. J., et al. (2026) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2026.1879243 · Cited by 1
“…use of linezolid in standardized 9-month regimens for treating drug-resistant tuberculosis (TB) during pregnancy, recommending baseline and follow-up laboratory monitoring (haemoglobin, platelets, neutrophils) (88), based on limited evidence of its use in a small number of pregnant women (89, 90).”
Hudu, S. A. (2022) · International Journal of Frontline Research in Multidisciplinary Studies · doi:10.56355/ijfrms.2022.1.1.0031 · Cited by 1
A Case of Multidrug-Resistant (MDR) Tuberculosis and HIV Co-Infection
Torres, S. G. V., Fullmer, J. C., & Berkowitz, L. (2023) · Cureus · doi:10.7759/cureus.37033 · Cited by 1
Recent Developments in the Treatment of Bacterial Pneumonia
Johnson, G., Young, M., Gordon, J., & Preuss, C. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-20521-7_13 · Cited by 2
Abubakar, A., Parsa, A. D., & Walker, S. (2023) · nternational Journal of Public Health Pharmacy and Pharmacology · doi:10.37745/ijphpp.15/vol8n12747 · Cited by 1
Naser, N., Abdulla, H., & Kadhem, H. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00225-0 · Cited by 1
Kalabukha, I. A., Maietnyi, I., & Vysotskyy, A. H. (2023) · Tuberculosis Lung Diseases HIV Infection · doi:10.30978/tb2023-2-36 · Cited by 1
“In a significant number of observations, the optimal and most effective measure is a combination of specific therapy with surgical treatment methods [10, 14, 18, 20].”
BackgroundOcular tuberculosis associated with Epstein-Barr virus myelitis: A case report
Alahyari, F., Halabian, R., & Nejad, J. H. (2024) · Infectious Medicine · doi:10.1016/j.imj.2024.100132 · Cited by 1
“Ocular TB, a rare manifestation, accounts for 1% to 2% of all TB cases [ 10 ].”
BackgroundThe Hidden Threat of Antimicrobial Resistance: A Case Study from A Private Hospital in Jordan
Mansour, G. H., Fararjeh, A., Shawagfeh, M. T., Laban, N. A., Alsarhan, A. A., Al-Shawabkeh, J. D., & Effendy, A. W. M. (2024) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.18.4.30 · Cited by 1
Thepa, P. C. A., Khethong, P. K. S., & Saengphrae, J. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.5340 · Cited by 2
Bakali, J. E., Błaszczyk, M., Evans, J. C., Boland, J. A., McCarthy, W. J., Fathoni, I., Dias, M. V. B., Johnson, E. O., Coyne, A. G., Mizrahi, V., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202300221 · Cited by 1
Ojo, O., Mmutlane, E. M., & Ndinteh, D. T. (2024) · Research Square · doi:10.21203/rs.3.rs-3967817/v1 · Cited by 1
Treatment strategies of patients with co-existing TB and LC: systematic reviews and meta-analysisPreprint
Zhang, H., Li, W., Chen, Y., chai, Y.-Q., Zhao, Y., & Gu, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1794116/v1
Zhang, Y., Pan, Z.-Y., Chen, J., Li, B.-X., Duan, Q., Li, Y., Han-li, R., & Gan, H. (2022) · Microbial Drug Resistance · doi:10.1089/mdr.2022.0015
Linezolid: prospects for use in antibiotic therapy
Bezdetko, N. V., & Mishchenko, O. Y. (2022) · Medicine of Ukraine · doi:10.37987/1997-9894.2022.1(257).264293
Metadata
- Authors
- Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T.
- Affiliations
- World Health Organization (CH)
- Corresponding author
- Mirzayev, Fuad
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-11-26
- Volume
- 57
- Issue
- 6
- Pages
- 2003300
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC8176349
- OpenAlex
- W3108150642
- Cited by
- 301
- References
- 23
- Citations by year
- 2026: 31 · 2025: 53 · 2024: 43 · 2023: 88 · 2022: 64 · 2021: 22
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- United States Agency for International Development
- Russian Federation
- Unitaid
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, bedaquiline, pretomanid, linezolid, delamanid, fluoroquinolone resistance, treatment duration, WHO treatment recommendations, antimicrobial resistance
- MeSH terms
- Linezolid, Antitubercular Agents, Drug Therapy, Combination, Female, Humans, Pregnancy, World Health Organization, Tuberculosis, Multidrug-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
